Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis
Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection wer...
Gespeichert in:
| Veröffentlicht in: | Bioscience reports 2020-06, Vol.40 (6) |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | |
| container_title | Bioscience reports |
| container_volume | 40 |
| creator | Liu, Baochi Cheng, Mingrong Chen, Xiaodong Li, Lei Si, Yanhui Wang, Shijia Wang, Ying Shi, Yufang |
| description | Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection were divided into two groups as follows: those who received (combination therapy group, 14 patients) and those who did not receive (routine therapy group, 7 patients) bone marrow cell transplantation through the portal vein. Two patients died of surgery-related complications in the combination therapy group. The results showed that the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than the 14.3% in the conventional therapy group (P |
| doi_str_mv | 10.1042/BSR20191316 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7313450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32520354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-f781ffb0c214057b6e27f97f14dfc5ab3a6fe23d679d67b903986fce9e2109f73</originalsourceid><addsrcrecordid>eNpVUE1LAzEQDaLYWj15l9xlNV-72VwELWoLBcGv65LNJt3IdrMkqcV_b6Ra6mEYZt6bNzMPgHOMrjBi5Pru5ZkgLDDFxQEY45zTjAmaH4IxwoxlJSvoCJyE8IEQSgA7BiNKcoJozsZgebuOrnNLtw6wdr2GK-m920Cluw5GL_swdLKPMlrXQ9vD2OrU1jKudB-hM3A2f4dDglMZ4MbGFiq3GnQfZNQNVNb71gUbTsGRkV3QZ795At4e7l-ns2zx9Dif3i4yRUscM8NLbEyNFMEM5bwuNOFGcINZY1QuayoLowltCi5S1AJRURZGaaEJRsJwOgE3W91hXa90o9JZXnbV4G167Kty0lb_kd621dJ9VpxiynKUBC63Asq7ELw2u1mMqh-_qz2_E_tif92O-2cw_QZvvn6N</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Liu, Baochi ; Cheng, Mingrong ; Chen, Xiaodong ; Li, Lei ; Si, Yanhui ; Wang, Shijia ; Wang, Ying ; Shi, Yufang</creator><creatorcontrib>Liu, Baochi ; Cheng, Mingrong ; Chen, Xiaodong ; Li, Lei ; Si, Yanhui ; Wang, Shijia ; Wang, Ying ; Shi, Yufang</creatorcontrib><description>Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection were divided into two groups as follows: those who received (combination therapy group, 14 patients) and those who did not receive (routine therapy group, 7 patients) bone marrow cell transplantation through the portal vein. Two patients died of surgery-related complications in the combination therapy group. The results showed that the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than the 14.3% in the conventional therapy group (P<0.01). After treatment, the liver function score decreased significantly in the combination therapy group at 1 (t = 4.276, P = 0.000), 3 (t = 9.153, P = 0.000), and 12 (t = 13.536, P = 0.000) months, the levels of albumin were significantly increased, and the total bilirubin level and prothrombin time were significantly reduced or shortened as compared with the routine therapy group (P<0.05 or <0.01). The white blood cell count, hemoglobin, platelet count, and CD4+ and CD8+ levels were significantly higher in the combination therapy group at different time points as compared with the routine therapy group (P<0.05 or <0.01). In summary, the combination therapy is effective in HIV-infected patients with DLC and useful for the recovery of liver function and cellular immune function but may increase the risk of severe complications after surgery.</description><identifier>ISSN: 0144-8463</identifier><identifier>EISSN: 1573-4935</identifier><identifier>DOI: 10.1042/BSR20191316</identifier><identifier>PMID: 32520354</identifier><language>eng</language><publisher>England: Portland Press Ltd</publisher><subject>Adult ; Anti-HIV Agents - adverse effects ; Anti-HIV Agents - therapeutic use ; Bone Marrow Transplantation - adverse effects ; Bone Marrow Transplantation - mortality ; Cell Cycle, Growth & Proliferation ; Diagnostics & Biomarkers ; Female ; Gene Expression & Regulation ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - mortality ; Humans ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - mortality ; Liver Cirrhosis - surgery ; Male ; Middle Aged ; Postoperative Complications - etiology ; Recovery of Function ; Risk Factors ; Splenectomy ; Stem Cells ; Time Factors ; Translational Science ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Bioscience reports, 2020-06, Vol.40 (6)</ispartof><rights>2020 The Author(s).</rights><rights>2020 The Author(s). 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-f781ffb0c214057b6e27f97f14dfc5ab3a6fe23d679d67b903986fce9e2109f73</citedby><cites>FETCH-LOGICAL-c381t-f781ffb0c214057b6e27f97f14dfc5ab3a6fe23d679d67b903986fce9e2109f73</cites><orcidid>0000-0001-9051-1223</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313450/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313450/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32520354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Baochi</creatorcontrib><creatorcontrib>Cheng, Mingrong</creatorcontrib><creatorcontrib>Chen, Xiaodong</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Si, Yanhui</creatorcontrib><creatorcontrib>Wang, Shijia</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Shi, Yufang</creatorcontrib><title>Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis</title><title>Bioscience reports</title><addtitle>Biosci Rep</addtitle><description>Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection were divided into two groups as follows: those who received (combination therapy group, 14 patients) and those who did not receive (routine therapy group, 7 patients) bone marrow cell transplantation through the portal vein. Two patients died of surgery-related complications in the combination therapy group. The results showed that the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than the 14.3% in the conventional therapy group (P<0.01). After treatment, the liver function score decreased significantly in the combination therapy group at 1 (t = 4.276, P = 0.000), 3 (t = 9.153, P = 0.000), and 12 (t = 13.536, P = 0.000) months, the levels of albumin were significantly increased, and the total bilirubin level and prothrombin time were significantly reduced or shortened as compared with the routine therapy group (P<0.05 or <0.01). The white blood cell count, hemoglobin, platelet count, and CD4+ and CD8+ levels were significantly higher in the combination therapy group at different time points as compared with the routine therapy group (P<0.05 or <0.01). In summary, the combination therapy is effective in HIV-infected patients with DLC and useful for the recovery of liver function and cellular immune function but may increase the risk of severe complications after surgery.</description><subject>Adult</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Bone Marrow Transplantation - mortality</subject><subject>Cell Cycle, Growth & Proliferation</subject><subject>Diagnostics & Biomarkers</subject><subject>Female</subject><subject>Gene Expression & Regulation</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Humans</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver Cirrhosis - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Postoperative Complications - etiology</subject><subject>Recovery of Function</subject><subject>Risk Factors</subject><subject>Splenectomy</subject><subject>Stem Cells</subject><subject>Time Factors</subject><subject>Translational Science</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>0144-8463</issn><issn>1573-4935</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUE1LAzEQDaLYWj15l9xlNV-72VwELWoLBcGv65LNJt3IdrMkqcV_b6Ra6mEYZt6bNzMPgHOMrjBi5Pru5ZkgLDDFxQEY45zTjAmaH4IxwoxlJSvoCJyE8IEQSgA7BiNKcoJozsZgebuOrnNLtw6wdr2GK-m920Cluw5GL_swdLKPMlrXQ9vD2OrU1jKudB-hM3A2f4dDglMZ4MbGFiq3GnQfZNQNVNb71gUbTsGRkV3QZ795At4e7l-ns2zx9Dif3i4yRUscM8NLbEyNFMEM5bwuNOFGcINZY1QuayoLowltCi5S1AJRURZGaaEJRsJwOgE3W91hXa90o9JZXnbV4G167Kty0lb_kd621dJ9VpxiynKUBC63Asq7ELw2u1mMqh-_qz2_E_tif92O-2cw_QZvvn6N</recordid><startdate>20200626</startdate><enddate>20200626</enddate><creator>Liu, Baochi</creator><creator>Cheng, Mingrong</creator><creator>Chen, Xiaodong</creator><creator>Li, Lei</creator><creator>Si, Yanhui</creator><creator>Wang, Shijia</creator><creator>Wang, Ying</creator><creator>Shi, Yufang</creator><general>Portland Press Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9051-1223</orcidid></search><sort><creationdate>20200626</creationdate><title>Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis</title><author>Liu, Baochi ; Cheng, Mingrong ; Chen, Xiaodong ; Li, Lei ; Si, Yanhui ; Wang, Shijia ; Wang, Ying ; Shi, Yufang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-f781ffb0c214057b6e27f97f14dfc5ab3a6fe23d679d67b903986fce9e2109f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Bone Marrow Transplantation - mortality</topic><topic>Cell Cycle, Growth & Proliferation</topic><topic>Diagnostics & Biomarkers</topic><topic>Female</topic><topic>Gene Expression & Regulation</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Humans</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver Cirrhosis - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Postoperative Complications - etiology</topic><topic>Recovery of Function</topic><topic>Risk Factors</topic><topic>Splenectomy</topic><topic>Stem Cells</topic><topic>Time Factors</topic><topic>Translational Science</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Baochi</creatorcontrib><creatorcontrib>Cheng, Mingrong</creatorcontrib><creatorcontrib>Chen, Xiaodong</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Si, Yanhui</creatorcontrib><creatorcontrib>Wang, Shijia</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Shi, Yufang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioscience reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Baochi</au><au>Cheng, Mingrong</au><au>Chen, Xiaodong</au><au>Li, Lei</au><au>Si, Yanhui</au><au>Wang, Shijia</au><au>Wang, Ying</au><au>Shi, Yufang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis</atitle><jtitle>Bioscience reports</jtitle><addtitle>Biosci Rep</addtitle><date>2020-06-26</date><risdate>2020</risdate><volume>40</volume><issue>6</issue><issn>0144-8463</issn><eissn>1573-4935</eissn><abstract>Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection were divided into two groups as follows: those who received (combination therapy group, 14 patients) and those who did not receive (routine therapy group, 7 patients) bone marrow cell transplantation through the portal vein. Two patients died of surgery-related complications in the combination therapy group. The results showed that the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than the 14.3% in the conventional therapy group (P<0.01). After treatment, the liver function score decreased significantly in the combination therapy group at 1 (t = 4.276, P = 0.000), 3 (t = 9.153, P = 0.000), and 12 (t = 13.536, P = 0.000) months, the levels of albumin were significantly increased, and the total bilirubin level and prothrombin time were significantly reduced or shortened as compared with the routine therapy group (P<0.05 or <0.01). The white blood cell count, hemoglobin, platelet count, and CD4+ and CD8+ levels were significantly higher in the combination therapy group at different time points as compared with the routine therapy group (P<0.05 or <0.01). In summary, the combination therapy is effective in HIV-infected patients with DLC and useful for the recovery of liver function and cellular immune function but may increase the risk of severe complications after surgery.</abstract><cop>England</cop><pub>Portland Press Ltd</pub><pmid>32520354</pmid><doi>10.1042/BSR20191316</doi><orcidid>https://orcid.org/0000-0001-9051-1223</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0144-8463 |
| ispartof | Bioscience reports, 2020-06, Vol.40 (6) |
| issn | 0144-8463 1573-4935 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7313450 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Bone Marrow Transplantation - adverse effects Bone Marrow Transplantation - mortality Cell Cycle, Growth & Proliferation Diagnostics & Biomarkers Female Gene Expression & Regulation HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - mortality Humans Liver Cirrhosis - diagnosis Liver Cirrhosis - mortality Liver Cirrhosis - surgery Male Middle Aged Postoperative Complications - etiology Recovery of Function Risk Factors Splenectomy Stem Cells Time Factors Translational Science Transplantation, Autologous Treatment Outcome |
| title | Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20bone%20marrow%20cell%20transplantation%20in%20the%20treatment%20of%20HIV%20patients%20with%20compensated%20cirrhosis&rft.jtitle=Bioscience%20reports&rft.au=Liu,%20Baochi&rft.date=2020-06-26&rft.volume=40&rft.issue=6&rft.issn=0144-8463&rft.eissn=1573-4935&rft_id=info:doi/10.1042/BSR20191316&rft_dat=%3Cpubmed_cross%3E32520354%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32520354&rfr_iscdi=true |